Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation
Authors:
- 1 January 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 16 (1) , 17-23
Abstract
Summary. Esophageal adenocarcinoma arising on a background of Barrett’s esophagus is increasing in incidence. A molecular understanding of both the progressionKeywords
This publication has 25 references indexed in Scilit:
- Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancerBritish Journal of Surgery, 2002
- Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancerBritish Journal of Surgery, 2001
- Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinomaCancer, 2000
- Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transferOncogene, 1998
- The Significance of c-erb B-2 and p53 Immunoreactivity in Patients with Adenocarcinoma of the EsophagusAnnals of Surgery, 1995
- Bcl-2 and the regulation of programmed cell deathJournal of Cell Biology, 1994
- bcl-2 Protein in Non-Small-Cell Lung CarcinomaNew England Journal of Medicine, 1993
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell deathCell, 1993
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990